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Introduction
Tetrahydrobiopterin (BH4) plays an important role in the vascular system, where it is synthesized in endothelial cells and -to lesser extent -in smooth muscle cells and fibroblasts via de novo and s alvage pathways (Nichol et al., 1983) . G uanosine trisphosphate cyclohydrolase I is the first and rate-limiting enzyme in the de novo biosynthetic pathway. It catalyzes hydrolysis of GTP to 7,8-dihydroneopterin trisphosphate, which is then converted to BH4 by the conse cutive action of 6-pyruvoyltetrahydropterin synthase and sep iapterin reductase. In addition to its de novo biosynthesis, BH4 is enzymatically regenerated from its oxidation products quinonoid 6,7[8H]-dihydrobiopterin and B H2 by dihydropteridine reductase and DHFR, respectively. Latter reaction is part of the so-called salvage pathway, in which sepiapterin is reduced by sepiapterin reductase to BH2, and further by DHFR to yield BH4 (Werner et al., 2011) .
As an essential cofactor of eNOS, BH4 promotes NO synthesis by facilitating the transfer of electrons from the reductase domain to the heme group for reductive activation of molecular O 2 , which is required for oxidation of the amino acid substrate L-arginine. At subsaturating concentrations of L-arginine or B H4, autoxidation of the ferrous-oxy and ferr ous-superoxy complexes results in release of superoxide anion and hydrogen peroxide, respectively, at the expense of the productive cycle yielding L-citrulline and NO (Gorren and Mayer, 2007) . This phenomenon, referred to as eNOS uncoupling, leads to simultaneous formation of NO and superoxide which rapidly combine to form peroxynitrite, an endogenous cy totoxin causing cellular dysfunction through oxidation of various biomolecules, in particular proteins and DNA (Calcerrada et al., 2011) .
Superoxide/peroxynitrite formation by unc oupled eNOS has been implicated in endothelial dysfunction associated w ith a v ariety of c ardiovascular diseases inc luding atherosclerosis, hypertension and diabetes. In accordance with the role of BH4 as "coupling switch", a causal MOL #79855 link between BH4 deficiency and endothelial dysfunction was found in many (though not all) animal models of vascular diseases. Moreover, administration of BH4 has been shown to restore endothelial function in patients with hypertension, diabetes m ellitus, hypercholesterolemia, atherosclerosis, coronary artery disease, chronic hear t failure, and in chronic smokers, suggesting that BH4 deficiency, resulting in eNOS uncoupling and limited NO bioavailability, may play a prominent role in the pathogenesis of cardiovascular diseases (Schmidt and Alp, 2007; Katusic et al., 2009; Vasquez-Vivar, 2009; Förstermann, 2010) .
In addition to preventing eNOS uncoupling, BH4 is also a powerful antioxidant, reacting with superoxide, H 2 O 2 , and peroxynitrite. Accordingly, the beneficial effects of BH4 could also be ascribed to the antioxidant properties of the pteridine. Some studies have focused on this issue by using NH4, a compound that exhibits similar antioxidative properties as BH4 but does not bind to eN OS, and the results are a mbiguous. In caveolin-1-deficient mice, an animal model for endothel ial dysfunction, vascular superoxide production was diminished after oral appli cation of B H4 but no t NH4 (Wunderlich et al., 2008) . S imilarly, in human studies performed with chronic smokers, endothelial-dependent vasodilation measured as forearm blood flow response to acetylcholine, was improved upon intra-arterial infusion of BH4 but not NH4 (Heitzer et al., 2000) . However, when endothelial dysfunction was induced by ischemia reperfusion injury in the forearm of healthy human subjects, both BH4 and NH4 exerted protective effects (Mayahi et al., 2007) . These data dem onstrate that at least under certain conditions of oxidative stress, the benefi cial effect of B H4 supplementation is not explained by the reversal of eNOS uncoupling.
In a recent study aimed at clarifying whether exposure of vascular tissue to GTN results in BH4 depletion, we showed that l ong-term treatment of cultured endothelial cells with GTN markedly diminished NO-induced cGMP formation in cells and cell extracts (Schmidt et al., 2010 ). Here we provide conclusive evidence that the apparent dysfunction of sGC results from GTN-triggered oxidation of enzy me-bound heme and dem onstrate that the oxidative MOL #79855 6 inactivation of sG C is prevented by supplementation of c ells with BH4, revealing a novel protective mechanism that might contribute to the beneficial vascular effects of BH4.
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Materials and Methods
Materials
BAY 60-2770 (Bayer AG, Wuppertal, Germany) was dissolved in DMSO. The stock solution (1 mM) was diluted with 50 % DMSO (v/v) in water to yield a BAY 60-2770 concentration of 0.1 mM. All further dilutions were made with water. The solvent (final concentration of DMSO in the assay ≤ 5 %) did neither affect basal nor NO-induced cGMP accumulation. DEA/NO (Sigma-Aldrich, Vienna, Austria) was dissolved and diluted in 10 mM NaOH. Nitropohl ® ampoules (G. Pohl-Boskamp GmbH. & Co, Hohenlockstedt, Germany), containing 4.4 mM GTN in 250 mM glucose, were obtained from a local pharmacy and diluted in water. Glucose vehicle controls had no effects. Sepiapterin, BH2, BH4, NH2, and NH4 were from Schircks Laboratories (Jona, Switzerland). Antibiotics and fetal calf serum were purchased from PAA Laboratories (Linz, Austria). Culture media and other chemicals were from Sigma-Aldrich (Vienna, Austria).
Culture and treatment of cells
Porcine aortic endothelial cells were isolated as described (Schmidt et al., 1989 ) and cultured at 37 °C, 5 % CO 2 , in Dulbecco´s modified Eagle´s medium, supplemented with 10 % (v/v) heat-inactivated fetal calf serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 1.25 µg/ml amphotericin B. Rat lung fibroblasts (RFL-6 cells) were obtained from ATCC and cultured in Ham's F-12 medium (37 °C, 5 % CO 2 ), containing 20 % (v/v) heat-inactivated fetal calf serum, 100 U /ml penicillin, 0.1 mg/ml streptomycin, and 1.25 µ g/ml amphotericin B.
Where indicated, cells were pretreated in culture medium containing GTN, methotrexate and/or pteridines.
Determination of cGMP formation
Accumulation of intracellular cGMP was determined as previously described (Schmidt et al., 1999) . Briefly, endothelial or RFL-6 cells grown in 24-w ell plates were washed and preincubated for 15 min at 37 °C in 50 mM Tris buffer, pH 7.4, containing 100 mM NaCl, 5 MOL #79855 mM KCl, 1 mM MgCl 2 , 2.5 mM CaCl 2 , 1 mM 3-isobutyl-1-methylxanthine, 1 µM indomethacin and, where indicated, ODQ (10 nM -10 µM). Reactions were started by addition of DEA/NO (1 µM) or BAY 60-2770 (10 nM -1 0 µM) and term inated after 4 m in by removal of the incubation medium and addition of 0.01 N HCl. Within 1 h, intracellular cGMP was completely released into the supernatant and measured by radioimmunoassay. Data were normalized to maximal cGMP formation induced by DEA/NO under control conditions.
Determination of sGC activity in cytosolic fractions of endothelial cells
Endothelial sGC activity was determined as previously described (Schmidt et al ., 2010) .
Briefly, endothelial cells grown in petri dishes (90 mm diameter) were incubated for 24 h at 37 °C in D MEM in th e absence a nd presence of 0.1 mM GTN and/or 0.1 m M sepiapterin.
Then cells were harvested and lysed by three cycles of freeze/thawing. Cytosolic fractions were obtained by centrifugation at 10,000 g for 10 min, and protein c oncentration was determined with the Bradford assay. For measuring sGC activity, cytosolic fractions (~0.2 mg of protein) w ere incubated for 10 min at 37 °C in a tota l volume of 0.1 ml of 50 mM triethanolamine/HCl buffer, pH 7.4, containing 0.5 mM [α- 32 P]GTP (~300,000 cpm), 3 mM MgCl 2 , 1 m M cGMP, 1 mM 3-isobutyl-1-methylxanthine, 10 mM phosphocreatine, 152 U/l creatine phosphate kinase,1 mM EGTA, and DEA/NO or p rotoporphyrin IX (10 µM, each).
Reactions were terminated by addition of 450 µl zinc acetate (120 mM) and 450 µl sodium bicarbonate (120 mM), followed by isolation of 32 P-cGMP by chromatography over A l 2 O 3 columns.
Determination of intracellular BH4 and BH2 levels
Cells grown in petri dishes (diameter 90 m m) were harvested (~5 x 10 6 per petri di sh), respectively, by interpolation in calibration curves that were established daily with authentic BH 2 (3 -300 nM) oxidized under acidic conditions. BH4 and BH2 levels were calculated from the amounts of biopterin measured after oxidation in acid (biopterin + BH2 + BH4), after oxidation in base (biopterin + BH2), or in non-oxidized samples (biopterin).
Spectral measurements
Stock solutions of oxyHb were freshly prepared each da y by dissolving 17 mg of bovine hemoglobin in 1 ml of 50 mM potassium phosphate buffer, pH 7.4. Subsequent to addition of sodium dithionite, the solution was passed over a Sephadex G-25 column, and oxyHb was BH4 is for med intracellularly from sepiapterin by the consecutive action of sepiapterin reductase and D HFR, which catalyze the red uction of sepiapterin to BH2 and further reduction of BH2 to BH4, respectively. Accordingly, treatment of the cel ls with sepiapterin usually results in an increase of both BH2 and BH4. To see whether sGC protection requires the fully reduced biopterin, we studied the effect of the DHFR inhibitor MTX (0.1 mM), which blocks BH2-to-BH4 conversion. MTX led to accumulation of BH2 (from 104 ± 30 to 554 ± 23 pmol/mg) that was accompanied by a decrease in BH4 levels close to that of untreated cells (13.3 ± 2.6 vs. 7.6 ± 0.6 p mol/mg). As shown in Fig. 2A , the effect of sepi apterin on DEA/NO-induced cGMP formation was virtually abolished in the presence of MTX, indicating that sGC is protected against oxidative inactivation by BH4 but not by BH2. To substantiate these results, we incubated the cells with BH2, added to the culture medium every 8 hours (final concentration of each application 0.1 mM) to account for t he oxidative loss of the pteridine during the 24-h incubation. As observed with sepiapterin, exogenously added BH2
This article has not been copyedited and formatted. The final version may differ from this version. prevented the effect of GTN in the absence but not in the presence of MTX, demonstrating that reduction to BH4 was essential to confer sGC protection. In contrast to BH2, NH2 added every 8 h to the cells had no effect 1 . Similarly, scavenging of superoxide and/or peroxynitrite with SOD (1000 U/ml), Tiron (10 mM), MnTBAP (0.1 mM) or urate (1 mM) did not prevent the effect of GTN on DEA/NO-induced cGMP accumulation (Fig. 2B) , excluding scavenging of reactive oxygen species as the underlying mechanism.
To confirm that the observed effects on endothelial cGMP levels do indeed reflect changes in sGC function rather than changes in the rates of cGMP hydrolysis or other indirect effects,
we measured sGC activity in cytosolic fractions of endothelial cells that had been incubated for 24 h with GTN in the absence or presence of sepiapterin. As shown in Fig. 3 , the data were identical to those obtained with intact cells. Specific sGC activity was decreased by about 50 % upon exposure of the cells to G TN and the effect of the or ganic nitrate was prevented by coincubation of the cells w ith GTN and sepi apterin. Activation of sGC by protoporphyrin IX, which acts through binding to he me-free sGC, was not affected by pretreating the cells w ith GTN, indicating that the effect of the orga nic nitrate is due to oxidation of ferrous sGC and subsequent loss of the ferric heme, as suggested previously (Schröder et al., 1988; Schrammel et al., 1996; Artz et al., 2002; Gorren et al., 2005; Schmidt et al., 2010) . Thus, the present data suggest that B H4 protects sGC-bound heme against oxidation.
To address this intriguing possibi lity we used BAY 60-2770 (Knorr et al., 2008) , a close chemical analog of BAY 58-2667 ( Cinaciguat) with a similar pharmacological profile.
Apparently acting as protoporphyrin IX mimetics, these drugs potently activate heme-free sGC without affecting the NO-sensitive ferrous enz yme (Roy et al., 2008; Hoffmann et al., 2009 ). In the absence of GTN, BAY 60-2770 increased cGMP formation to ~50 % of the rate achieved by DEA/NO, indicating that untreate d endothelial cells may already contain a substantial amount amount of heme-free sGC (Fig. 4A) . Exposure of the cells for 24 h to The data obtai ned with GTN were confirmed with ODQ, a potent s GC inhibitor that a cts through heme oxidation (Schrammel et al., 1996) . As shown in (Fig. 5B) . Of note, short-term incubation with BH2 and BH4 resulted in intracellular BH4 levels significantly lower than those achieved by long-term incubation with sepiapterin (36.7 ± 6.0 and 12.7 ± 0.8 pmol /mg protein with BH2 and BH4, respectively, vs. 240 ± 35 pmol/mg protein). As observed w ith GTN-treated cells (see Fig. 2A ), preincubation with 0.1 mM NH2 for 1 h had no effect, whereas NH4 caused a 6-fold rightward shift of the ODQ concentration-response curve (Fig. 5C) , suggesting insufficient uptake and/or reduction of NH2 by endothelial cells.
Some key experiments were repeated with RLF-6 cells to see whether the observed effects of the reduced pteridines reflect a specific feature of endothelial cell s. The data s hown in This article has not been copyedited and formatted. The final version may differ from this version. 
NH2 (panel C).
To investigate whether BH4 also interacts with other hemoproteins, we monitored the UV/Vis absorption spectra of deoxyHb, which contains a similar heme group as sGC, after administration of ODQ and BH4. As shown in Fig. 7 , addition of ODQ (10 µM) to deoxyHb (10 µM) caused rapid oxidation to metHb, which was reversed upon addition of 100 µM BH4.
These results demonstrate that BH4 is able to regenerate oxyHb from metHb, implying that heme reduction by BH4 is not spe cific for sG C. 
Discussion
There is a large bod y of evidence indi cating that BH4 improves endothelial function in cardiovascular diseases by two mechanisms that m ay operate in a s ynergistic manner (Förstermann, 2010) . As an essential cofactor of eN OS, BH4 prevents uncoupling of reductive O 2 activation from L-arginine oxidation and thereby ensures maximal NO synthesis without concomitant formation of superoxide and peroxynitrite (Gorren and Mayer, 2007) . In addition, BH4 is a fairly efficient scavenger of superoxide and peroxynitrite and, therefore, reduces oxidative stress as endogenous antioxidant. Surprisingly, the pr otection of sG C against oxidative inactivation described here appears to reflect a novel effect of BH4 that is unrelated to both eNOS uncoupling and superoxide/peroxynitrite scavenging.
The prosthetic heme group of sGC represents the intracellular receptor for NO. Upon binding to the ferrous heme, NO induces a change in heme geometry resulting in enzyme activation and enhanced conversion of GTP to cGMP (Ignarro, 1992; Denninger and Marletta, 1999; Koesling et al., 2004) . Oxidation of the heme iron to its ferric form prevents NO binding and renders the enzy me insensitive to a ctivation by NO. Moreover, heme oxidation promotes dissociation of the heme from sGC (Roy et al., 2008) and induces degradation of the protein by the ubiquitin-proteasome pathway (Hoffmann et al., 2009; Meurer et al., 2009) . In contrast to NO, which requires ferrous he me iron for bind ing, the NO-and heme-independent sGC activators, e.g. B AY 58-2667 or BAY 60-2770, bind with high affinity to the heme-binding pocket of the apoenzyme (Schmidt et al., 2004; Martin et al., 2010) . Initially it was proposed that these drugs activate sGC if either the heme iron is oxidized or the heme group is missing (Stasch et al., 2002) , but recent dat a suggest that ox idation results in dissociation of the ferric heme group, with heme-free sGC being the sole target for this class of sGC activators (Roy et al., 2008) . Based on their unique mechanism of action, BAY 58-2667 and analogs are useful tools to determine the fraction of heme-free sGC in cells and tissues under various physiological or pathophysiological conditions (Stasch et al., 2006; Roy et al., 2008; Ahrens et al., 2011; Hoffmann et al., 2011) .
This article has not been copyedited and formatted. The final version may differ from this version. Both functional and spectroscopic data published pr eviously clearly indicate that GTN and ODQ oxidize the ferrous heme iron of sGC, resulting in loss of NO sensitivity of the enzyme (Schröder et al., 1988; Schrammel et al., 1996; Artz et al., 2002; Gorren et al., 2005; Schmidt et al., 2010) . Early studies by Ignarro and coworkers showed that the heme-free enzyme is activated by protoporphyrin IX (Ignarro et al., 1982) , and the new sGC activators, including BAY 60-2770 (Knorr et al., 2008) appear to act as highly potent protoporphyrin IX mimetics that activate heme-free sGC formed subsequent to oxidation by ODQ (Roy et al., 2008; Hoffmann et al., 2011) . Our results showing that exposure of cells to both GTN or ODQ led to converse effects on the cGMP response to DEA/NO and BAY 60-2770 agree well with these previous reports, but there were notable differences between the effects of GTN and ODQ.
While ODQ caused rapid inhibition of cGMP accumulation within 15 min, the effect of GTN occurred with a lag ti me of about 30 min, with maximal inhibition requiring 6 -8 h of incubation (see Fig. 1A ). Considering the h igh lipophilicity of GTN and oxidation of purified sGC within minutes (Gorren et al ., 2005) , this slow mode of a ction is hardly explained by delayed cellular uptake or slow binding of the drug to sGC. Based on literature reports on oxidation of sGC-bound heme by reactive oxygen species (Stasch et al., 2006; Boerrigter et al., 2007; Zhou et al., 2008 ) and a recent study from our laboratory showing that exposure of endothelial cells to GTN led to s low formation of superox ide (Schmidt et al., 2010) , w e speculated that the effect of GTN could be mediated by superoxide or peroxynitrite generated by uncoupled eN OS or ot her sources. However, neither NO synthase inhibition nor ascorbate (Schmidt et al., 2010) which has been shown to protect sGC-bound heme against oxidation by ODQ (Schrammel, 1996) . Further work is necessary to clarify this issue.
The observation that BH4 supplementation of cells protects sGC against inactivation by GTN and ODQ independently of i ts known antioxidative functions was unexpected. The BH4 precursor sepiapterin proved to be ideal for long-term incubations. The compound is fairly stable in aqueous s olution under aerobic conditi ons (Dantola et al., 2008) and efficiently taken up by endothelial cells (Ohashi et a l., 2011) . I ntracellular BH4 levels are rapid ly increased and remain constantly high for up to 2 days after addition of sepiapterin to the cell culture medium (K. Schmidt, unpublished observation). In contrast to sepiapterin, BH2 and BH4 are prone to autoxidation (Davis et al., 1988; Mayer et al., 1995; Dantola et al., 2008) and according to our own data, 10 -20 % of BH2 and ~99 % of BH4 are lost within 1 h incubation in culture medium (K. Schmidt, unpublished observations). Consequently, the increases in i ntracellular BH4 observed upon ex ogenous addition of BH2 or BH4 were transient and less pronounced than those observed with sepiapterin. Accordingly, we used BH2/BH4 supplementation only in short-term experiments or -in the case of long-ter m studies -re-added BH2 to the cultu re medium every 8 h. To test for a potential role of endogenous BH4, we inhibited BH4 biosynthesis by treating endothelial cells for 24 h with the guanosine tri sphosphate cyclohydrolase I inhibitor, 2,4 -diamino-6-hydroxypyrimidine.
Despite pronounced reduction of intracellular BH4 levels from 7.6 ± 0.6 to 0.3 ± 0.1 pmol/mg protein, the response to GTN remained unaltered (Supplemental Fig. 1 ), indicating that basal levels of BH4 are not sufficient to protect sGC against inactivation. Using the same experimental protocol that was established for supplementation of cells with reduced biopterins, we observed that NH4 mimicked the effect of BH4 on both endothelial cells and fibroblasts, further confirming that the protective effects of the pteridines are unrelated to the function of eNOS, which does not accept N H4 as a cofactor (Gorren et al., 1998) . However, in contrast to BH2, NH2 had no effect, indicating inefficient uptake and/or reduction to the corresponding tetrahydro derivative by DHFR. The mechanisms of cellular uptake and This article has not been copyedited and formatted. The final version may differ from this version. The protection of the heme by BH4 is not pe culiar to sGC, since BH4 is able to reverse the oxidation of deoxy Hb by ODQ (this study) and to reduce ferric ytochrome c (C apeillere- Blandin et al., 2005) . The reaction apparently involves a direct, one electron transfer from BH4 to the heme iron, with intermediate formation of a BH4 cation radical (Mathieu et al., 2004) . Using 6,7-dimethyltetrahydropterin, which exhibits electrochemical properties very similar to those of BH4 (Gorren et al., 2001) , Mansuy and coworkers demonstrated that only Preclinical and clinical data obtained with BAY 58-2667 suggest that the relative amount of heme-free vascular sGC is increased in cardiovascular disorders like coronary artery disease, pulmonary hypertension and chronic heart failure (Boerrigter et al., 2007; Lapp et al., 2009; Ahrens et al., 2011) . I n view of the es sential role of ox idative stress in most cardiovascular diseases (Strobel et al., 2011) , this is probably due to oxidation by reactive oxygen species and subsequent dissociation of sGC-bound heme. Partial dysfunction of sGC may cause NO resistance of the diseased blood vessels, resulting in increased blood pressure and atherosclerosis. The present data clearly demonstrate that BH4 protects sGC This article has not been copyedited and formatted. The final version may differ from this version. We did not treat cells for the 24 h period with the labile tetrahydropteridines, since more than 99% of BH4 was found to be lost within the first hour of incubation. 
